Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC) is a biopharmaceutical company focused on developing innovative cancer therapies. On July 7, 2025, CYCC will undergo a reverse stock split at a ratio of 15 for 1. This means that every 15 shares of the company's common stock will be consolidated into one share. The reverse stock split aims to increase the stock price and maintain compliance with NASDAQ listing requirements.
The reverse stock split will take effect on July 7, 2025, and trading on a split-adjusted basis will begin at the market open on that day. Despite the split, CYCC will continue to trade under the same symbol on The Nasdaq Capital Market. The new CUSIP number for the common stock will be 23254L876. This change is part of the company's strategy to enhance its stock's marketability and attract a broader range of investors.
Currently, CYCC's stock is priced at $0.236, reflecting a decrease of 4.80% with a change of $0.0119. The stock has fluctuated between a low of $0.215 and a high of $0.25 today. Over the past year, CYCC has experienced significant volatility, with a high of $39.84 and a low of $0.215. The company's market capitalization stands at approximately $5.6 million, indicating its relatively small size in the biopharmaceutical industry.
The trading volume for CYCC today is 2,594,625 shares, suggesting active investor interest. The reverse stock split is expected to consolidate the number of shares, potentially leading to a higher stock price. This move could help CYCC maintain its NASDAQ listing and improve its appeal to institutional investors who often have minimum price requirements for stock investments.
